| INTRODUCTION
Flow cytometry (FC) is essential for the characterization of B-cell lymphoproliferative disorders (B-LPD). In particular, the expression of the 5 markers included in the Moreau score (CD5, CD23, CD79b, FMC7, and intensity of surface Immunoglobulin [sIg] ) is used for the classification of many B-LPD. 1 Patients fulfilling ≥4 Moreau criteria are overwhelmingly more likely to have chronic lymphocytic leukemia (CLL) as opposed to any other B-LPD. 1 Conversely, fulfillment of ≤3 criteria by a B-LPD, in the absence of a tissue biopsy and its histological examination, is not diagnostic of any specific entity because the predictive value for CLL is low. [1] [2] [3] However, antigenic expression is a continuum rather than a dichotomic process, and B-LPD may evolve or show differences based on the involved anatomic site. Therefore, we set out to analyze the changes in the Moreau score in a series of patients with B-LPDs from whom more than one sample was analyzed.
| MATERIALS AND METHODS
All patients with more than one sample involved by a B-LPD between January 2010 and December 2016 were considered for this study.
Patients with disorders characterized by the expression of highly specific markers (ie, CD10 or CD123) were excluded, as were those diagnosed with mantle cell lymphoma with translocation t (11;14) , given that the Moreau score is irrelevant in these cases. The remaining cases were all included, regardless of lymphocyte count. This study was approved by the internal review board (REF. CEI: PI-17-178).
The main purpose of the study was (i) to determine the percentage of these patients who showed inconsistencies in the expression of the antigens that make up the Moreau score and (ii) the characterization of these differences.
One hundred and thirty-eight patients and 316 samples fulfilled the criteria for study entry, including 105 patients with 2 samples, 27 with 3 samples, 5 with 4 samples, and 1 with 5. Seventy-eight patients had a diagnosis of CLL/small lymphocytic lymphoma/CLL-phenotype monoclonal B-cell lymphocytosis. The rest had other diagnoses, largely non-CLL non-nodal B-LPD with exclusive Peripheral blood (PB) and/ or bone marrow (BM) involvement, without a histological diagnosis.
The samples were as follows: PB (n = 209), BM (n = 42), lymph node (LN) excision (n = 43) and LN fine needle aspiration (FNA, n = 14) and malignant effusion (n = 8).
Samples were processed as previously described. 4 kappa/lambda light chain restriction, were excluded. We also excluded cases with two clearly distinct (clonal) populations, that is, with obviously different expression of at least two antigens. We did not exclude patients with a double population with the same kappa or lambda light chain restriction (or with negative sIg) or with a sIg smear pattern. In a subanalysis of this study, patients with these patterns ( Figure 1 ) were compared with patients with a standard sIg image.
Frequencies and percentages are given for categorical variables while, for continuous variables, median and interquartile range (IQR) are provided. For comparisons involving categorical variables, the Fisher exact test was used. After adjustment for multiple comparison testing, statistical significance was set at P < .005.
| RESULTS
As mentioned, 138 patients and 316 samples were included. In 94 (68%) patients, all samples showed an identical Moreau score with positivity for the same markers, while in 44 (32%) patients, there was at least one antigenic inconsistency among their samples. There was one single inconsistency in 35 patients and two inconsistencies in 9.
In all, there were 53 antigenic differences affecting FMC7 (n = 18), CD79b (n = 12), CD23 (n = 12), sIg (n = 6), and CD5 (n = 5). We also determined the expression of CD43, which we have previously described as of potential aid in the differential diagnosis of complex cases. 4 It was inconsistent in only 3 cases. CD200 was inconsistent in 6 of 67 (9%) patients in whom it was assessed in at least two samples.
We then looked for factors that predicted for inconsistent antigenic expression. (Table 2b) .
In December 2010, we changed from a 4-to a 5-color antibody panel. With this, there were changes in antibody-fluorochrome combinations (Table 1) . Patients with one sample obtained before and one after December 2010 were not more likely to show antigenic inconsistencies than those with samples all obtained either before or after that date (7 of 12 vs 87 of 126, P = .52).
As the finding of trisomy 12 (tri12) in CLL (or CLL-phenotype monoclonal B-cell lymphocytosis) has been associated with a lower
Moreau score, 8, 9 we analyzed antigenic changes based on cytogenetic group among patients with CLL. The only groups large enough to consider separately were tri12 (18 cases, of which 8 were consistent) and 13q deletion (del13q) (31 cases, of which 21 were consistent) (P = .13).
Three cases had both tri12 and del13q and are counted in both groups.
Given that CLL is generally diagnosed with a Moreau score ≥4, we checked the potential clinical relevance of the antigenic changes.
T A B L E 2 Antigenic consistency based on the (a) number of samples corrected by the anatomic site of those samples and (b) surface immunoglobulin histogram pattern 
F I G U R E 2
In only one patient among 138, the Moreau score changed from 2 to 4 in two samples (peripheral blood, upper row, with a Moreau score of 4 and lymph node, lower row, with a Moreau score of 2). Cytogenetic analysis showed a homozygous chromosome 13 deletions in both samples, but IGH rearrangement testing was not performed
Seventeen patients (17 of 138, 12%) had a score ≥4 in one sample and ≤3 in another. Of those, in 3 cases, there was a histological sample diagnostic of small lymphocytic lymphoma. In 8 of 9 further patients with available clinical information, CLL was the diagnosis made by the clinician, even though a majority of patients had an indolent disorder with nonspecific cytogenetic findings. In only one patient, the Moreau score changed from 2 to 4 ( Figure 2 ) and the clinical diagnosis was CLL.
Nine patients (9 of 138, 6.5%) had a score of ≤2 in one and 3 in another. Of those, one had a histological diagnosis of marginal zone lymphoma and one was diagnosed by their physician with "atypical CLL." In the remainder (5 of 7 with available clinical data), the working diagnosis was that of an unspecified B-LPD with PB involvement.
| DISCUSSION
In this study, we found inconsistencies in the expression of the antigens in the Moreau score in an unexpectedly high proportion of cases.
The clinical implication of these inconsistencies, however, appears to be limited. Immunophenotypic inconsistencies are not rare in hematological malignancies, but they are often related to targeted therapies (such as anti-CD20 therapy in non-Hodgkin lymphoma patients leading to CD20-negative relapses) or to leukemic relapses with a more immature phenotype than at diagnosis. Neither of these can explain the large degree of inconsistencies in our cohort.
While the search for factors predictive of antigenic inconsistencies yielded limited results, some relevant information was obtained.
The most important factor associated with antigen inconsistencies was the site from where the sample was obtained. Samples obtained from different sites were more likely to show antigenic differences.
This could reflect cellular adaptation to different microenvironments, such as LN or BM, where they are in close contact with other neoplastic and non-neoplastic cells, unlike in PB or malignant effusions. Indeed, the lack of differences between patients with samples obtained before/after December 2010 and those with samples all obtained either before or after also supports the idea that inconsistencies are due to true antigenic changes rather than technical factors.
We found only a trend toward statistical significance between a double/smear image in sIg and other antigenic inconsistencies. This is probably due to the fact that patients with a double or smear pattern in the sIg histogram are not a homogenous group. On the one hand, technical factors probably play a role, as they do in sIg expression in malignant effusions. 5, 6 Indeed, it seems that sIg is more easily lost from malignant cells than normal B cells, 10 which would explain complete or partial loss of sIg (resulting in a double or smear pattern).
On the other hand, although anecdotic, none of the 4 patients with a persistent double image in sIg had a consistent immunophenotype,
suggesting that a few patients could have a biphenotypic or biclonal disease, even though we excluded all cases with clear evidence of that.
Unfortunately, this being a retrospective study, IGH V(D)J gene rearrangement could not be performed.
Interestingly, there were no differences between cases with tri12 and del13q, underscoring that the immunophenotypic particularities of tri12 8, 9 remain as constant as the more antigenically standard CLL with del13q.
Previous studies have focused on the value of specific antigens for the diagnosis of CLL and the classification of B-LPD, 11-13 but we are unaware of any that have assessed the reproducibility of the Moreau score. In this case, given that every patient acts as its own control, all immunophenotypic changes should be due to a change in the neo- ) and a modified CLL score including CD200 was recently published. 15 Other markers, such as CD160 or CD148, have also been explored. 16, 17 In our case, we have found CD43 of some value 4 and this study shows that its expression is particularly robust.
This study has limitations that must be acknowledged. Importantly, there are no data concerning the treatments patients received.
Although there is no evidence that the expression of any of the antigens analyzed would be modified by any treatment in currently use, the study would have benefited from this data in being able to assess this possibility. Secondly, we could not assess whether any specific disorder is more likely to show antigenic changes, but this is an inherent limitation in a study that largely includes B-LPD without a histological diagnosis (either due to lack of histological exam of potentially involved tissue or, more likely, due to lack of involvement of any organ other than PB). B-LPD without a specific histological diagnosis are frequent findings in the FC laboratory but have gone largely unexamined, precisely because the lack of a definitive diagnosis makes their rigorous study particularly complex. Finally, genetic data 18, 19 would have helped in establishing the biological diagnosis, which could have then provided a solid gold standard for the difficult cases.
In conclusion, this study found antigenic inconsistencies in the Moreau score in 32% of patients, particularly those with samples from different sites, warning against establishing a specific diagnosis based on a single FC study alone, especially in borderline cases, and underscoring the need for more precise diagnostic tools for this minority of patients even if the practical relevance of these diagnostic changes is questionable.
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